Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer
Conditions
Squamous NSCLC
Conditions: Keywords
Efficacy, Dovitinib, Squamous NSCLC
Study Type
Interventional
Study Phase
Phase 2
Study Design
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention
Name: Dovitinib
Type: Drug
Overall Status
Recruiting
Summary
Efficacy of Dovitinib for Squamous NSCLC.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 20 Years
Gender: Both
Criteria: Inclusion Criteria:

- histologically confirmed squamous NSCLC

- Previously treated with one or two lines of chemotherapy

- FGFR amplification (FISH > 5 copies of genes)

- 20 years or older

- ECOG PS 0-2

Exclusion Criteria:

- active infection

- uncontrolled brain metastasis

- unstable angina or MI
Location
Samsung Medical Center
Seoul, Korea, Republic of
Status: Recruiting
Contact: Myung-Ju Ahn, Ph.D. - 822-3410-3459 - silkahn@skku.edu
Start Date
March 2013
Sponsors
Samsung Medical Center
Source
Samsung Medical Center
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page